- Home
- GXO vs GRFS Comparison
GXO vs GRFS Comparison
Compare GXO & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXO
- GRFS
- Stock Information
- Founded
- GXO 2021
- GRFS 1940
- Country
- GXO United States
- GRFS Spain
- Employees
- GXO N/A
- GRFS N/A
- Industry
- GXO Transportation Services
- GRFS Biotechnology: Pharmaceutical Preparations
- Sector
- GXO Consumer Discretionary
- GRFS Health Care
- Exchange
- GXO Nasdaq
- GRFS Nasdaq
- Market Cap
- GXO 5.9B
- GRFS 5.5B
- IPO Year
- GXO N/A
- GRFS 2006
- Fundamental
- Price
- GXO $41.98
- GRFS $7.51
- Analyst Decision
- GXO Strong Buy
- GRFS Strong Sell
- Analyst Count
- GXO 12
- GRFS 1
- Target Price
- GXO $66.33
- GRFS N/A
- AVG Volume (30 Days)
- GXO 1.6M
- GRFS 1.3M
- Earning Date
- GXO 02-11-2025
- GRFS 01-01-0001
- Dividend Yield
- GXO N/A
- GRFS N/A
- EPS Growth
- GXO N/A
- GRFS N/A
- EPS
- GXO 0.89
- GRFS 0.27
- Revenue
- GXO $11,049,000,000.00
- GRFS $7,814,096,584.00
- Revenue This Year
- GXO $20.94
- GRFS $8.86
- Revenue Next Year
- GXO $10.35
- GRFS $7.00
- P/E Ratio
- GXO $47.17
- GRFS $33.24
- Revenue Growth
- GXO 14.44
- GRFS 7.21
- 52 Week Low
- GXO $41.95
- GRFS $5.30
- 52 Week High
- GXO $63.33
- GRFS $12.15
- Technical
- Relative Strength Index (RSI)
- GXO 13.88
- GRFS 44.79
- Support Level
- GXO $49.40
- GRFS $7.41
- Resistance Level
- GXO $50.85
- GRFS $8.13
- Average True Range (ATR)
- GXO 1.63
- GRFS 0.31
- MACD
- GXO -0.99
- GRFS 0.06
- Stochastic Oscillator
- GXO 0.16
- GRFS 45.13
About GXO GXO Logistics Inc.
GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.
About GRFS Grifols S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.